Regeneron Pharmaceuticals Q2 2023 Earnings Preview
Regeneron Pharmaceuticals (NASDAQ:REGN) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.
The consensus EPS Estimate is $9.90 (+1.3% Y/Y) and the consensus Revenue Estimate is $3.02B (+5.6% Y/Y).
Over the last 2 years, REGN has beaten EPS estimates 100% of the time and has beaten revenue estimates 100% of the time.

Over the last 3 months, EPS estimates have seen 2 upward revisions and 16 downward. Revenue estimates have seen 2 upward revisions and 13 downward.
The stock is rated a Buy by Wall Street analysts, as opposed to a Hold by Seeking Alpha's Quant Rating system, which has raised concerns about growth and valuation.

More on Regeneron Pharmaceuticals

Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening
Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefront
Regeneron: Eylea Hype Past, But '23 H2 Will Be A Gut Check